What Has Changed During the COVID-19 Pandemic? - The Effect on an Academic Breast Department in Portugal

Simão, Diana; Sardinha, M.; Reis, Ana Filipa; Spencer, Ana Sofia; Luz, Ricardo da; Oliveira, Sónia da Conceição Freitas

doi:10.4274/ejbh.galenos.2021.2021-11-1

Cited by 5 publications

(7 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Many studies discussed the changes in staging trends before and after the pandemic. 12,26–28 A study conducted in the United Kingdom by Borsky et al reported an increase in node-positive disease on presentation in 2020 compared to 2019 (36.2% vs. 23.6%, p = 0.0063), an increase in metastatic disease at presentation (8.0% vs. 2.9%, p = 0.0295) and increased in median UICC TNM stage at detection from 1b to 2a ( p = 0.0184). Conversely, a Turkish study by Kara et al did not find any statistically significant differences in tumor size, nodal involvement, or overall TNM stage.…”

Section: Discussionmentioning

confidence: 99%

“…6 In a subsequent study conducted in Portugal, the number of patients with advanced forms of BC who were admitted for the first time decreased by 40%. 12 Another multi-institutional study found a decrease in BC screenings and diagnosis during the COVID-19 pandemic with a change in disease staging distribution, with more patients diagnosed with stage IIB and IV during the pandemic. 13…”

Section: Introductionmentioning

confidence: 99%

“…9,10 The pandemic has significantly impacted the BC patient population with a decrease in screening programs and demanding access to healthcare facilities, leading to a decline in diagnosis and a shift in disease stage distribution at presentation. 9,11,12 The number of patients screened by the majority of active cancer screening programs, including BC screening, decreased during the pandemic, 11 as a study by London et al found a dramatic decline in BC screening by 89.2%. 6 In a subsequent study conducted in Portugal, the number of patients with advanced forms of BC who were admitted for the first time decreased by 40%.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Changes in breast cancer staging trends among Egyptian women after COVID-19: A retrospective single-center study

Wahab

Ibrahim

Gado

et al. 2023

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

Objectives Since being declared a global pandemic, the SARS-CoV-2 virus had a significant impact on the entire globe. The pandemic has placed a heavy burden on healthcare systems worldwide, and cancer patients are particularly prone. Despite the fact that initial international reports suggest delays in breast cancer (BC) diagnosis and screening programs, the Egyptian context requires additional research on this topic. To examine whether COVID-19 has changed the pattern of disease presentation before and after the pandemic, focusing on the tumor, node, and metastasis (TNM) staging of the disease at the initial presentation Methods This single-center, retrospective study of female BC patients initially diagnosed at Baheya Foundation was conducted during the following time frames: from Jan 2019 to Jan 2020 (Pre COVID-19 cohort) and from Mar 2020 to Mar 2021 (post–COVID-19 cohort). We compared the two cohorts in terms of clinical characteristics, tumor characteristics, and the number of days from presentation to treatment. Our primary endpoint was the difference in the TNM stage of BC at the initial presentation. Results This analysis included 710 BC patients, 350 from the pre-COVID cohort and 360 from the post-COVID group. We detected a 27.9% increase in late-stage BC (stages III-IV) in the post-pandemic cohort compared to the pre-pandemic (60.1% vs. 47%, p < 0.001). The time from diagnosis to commencement of treatment was significantly longer (28.34 ± 18.845 vs 36.04 ± 23.641 days, p < 0.001) in the post-COVID cohort (mean difference = 7.702, 95% CI 4.54–10.85, p < 0.001). A higher percentage of patients in the post-pandemic cohort received systemic neoadjuvant therapy ( p-value for Exact’s test for all treatment options = 0.001). Conclusions The number of patients requiring systemic neoadjuvant chemotherapy increased dramatically in the post-pandemic group with advanced stages of BC at presentation. This study highlights the need for proper management of cancer patients during any future pandemic.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Changes in breast cancer staging trends among Egyptian women after COVID-19: A retrospective single-center study

Wahab

Ibrahim

Gado

et al. 2023

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

show abstract

“…Outro estudo, com dados do Reino Unido, encontrou, durante a pandemia, aumento significante do estágio da doença à apresentação inicial, bem como dos casos com acometimento linfonodal e doença metastática 25 . Já em um centro de Portugal houve aumento significante na proporção de pacientes admitidas pela primeira vez para terapia sistêmica com câncer de mama metastático 26 .…”

Section: Região Mês 2021 Jan Fev Mar Abr Maiunclassified

COVID-19 e rastreamento do câncer de mama no Brasil: uma análise comparativa dos períodos pré-pandêmico e pandêmico

Furlam

Gomes

Machado

2023

Ciênc. saúde coletiva

View full text Add to dashboard Cite

Resumo Objetivou-se avaliar os impactos da COVID-19 no rastreamento do câncer de mama no Brasil. Coletaram-se dados do Sistema de Informações Ambulatoriais referentes a “mamografia bilateral para rastreamento” de janeiro/2015 a dezembro/2021. As análises foram feitas por região e para o Brasil. Calculou-se a média de exames em cada mês do ano com base nos dados de 2015 a 2019, a qual foi comparada, mensalmente, com o quantitativo de exames em 2020 e 2021, obtendo-se a diferença bruta e percentual entre esses valores. A mesma análise foi realizada para o número total de exames em 2020 e 2021, individualmente, e para os dois anos em conjunto. Em 2020 houve quedas no número de exames que variaram de 25% (Norte) a 48% (Nordeste), culminando em 1,749 milhão de exames a menos no país (queda de 44%). Em 2021, a região Centro-Oeste apresentou quantitativo de exames 11% superior ao esperado, enquanto as demais regiões apresentaram quedas entre 17% (Norte) e 27% (Sudeste/Sul), culminando em negativo de 927 mil exames no país (redução de 23%). Na análise conjunta (2020/2021), encontraram-se reduções que variaram de 11% (Centro-Oeste) a 35% (Sudeste/Sul), culminando em negativo de 2,676 milhões de procedimentos no Brasil (queda de 33%).

show abstract

“…45 Other studies in the US, South America, Europe, the Middle East, and Asia, obtained similar results. [12][13][14]30,43,[46][47][48][49] Studies showing no tumor shift, as displayed in the presented results, are scarce, 11,15 but may also have been underreported. Our study showed no difference in terms of frequency and modalities of breast reconstruction surgery in 2020 compared to 2019, unlike other studies that found less breast reconstruction surgeries post-pandemic, in consistence with scientific recommendations.…”

mentioning

confidence: 93%

Impact of the COVID‐19 pandemic on clinical presentation, treatments, and outcomes of new breast cancer patients: A retrospective multicenter cohort study

Guével,

Priou,

Lamé

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

BackgroundThe SARS CoV‐2 pandemic disrupted healthcare systems. We compared the cancer stage for new breast cancers (BCs) before and during the pandemic.MethodsWe performed a retrospective multicenter cohort study on the data warehouse of Greater Paris University Hospitals (AP‐HP). We identified all female patients newly referred with a BC in 2019 and 2020. We assessed the timeline of their care trajectories, initial tumor stage, and treatment received: BC resection, exclusive systemic therapy, exclusive radiation therapy, or exclusive best supportive care (BSC). We calculated patients' 1‐year overall survival (OS) and compared indicators in 2019 and 2020.ResultsIn 2019 and 2020, 2055 and 1988, new BC patients underwent cancer treatment, and during the two lockdowns, the BC diagnoses varied by −18% and by +23% compared to 2019. De novo metastatic tumors (15% and 15%, p = 0.95), pTNM and ypTNM distributions of 1332 cases with upfront resection and of 296 cases with neoadjuvant therapy did not differ (p = 0.37, p = 0.3). The median times from first multidisciplinary meeting and from diagnosis to treatment of 19 days (interquartile 11–39 days) and 35 days (interquartile 22–65 days) did not differ. Access to plastic surgery (15% and 17%, p = 0.08) and to treatment categories did not vary: tumor resection (73% and 72%), exclusive systemic therapy (13% and 14%), exclusive radiation therapy (9% and 9%), exclusive BSC (5% and 5%) (p = 0.8). Among resected patients, the neoadjuvant therapy rate was lower in 2019 (16%) versus 2020 (20%) (p = 0.02). One‐year OS rates were 99.3% versus 98.9% (HR = 0.96; 95% CI, 0.77–1.2), 72.6% versus 76.6% (HR = 1.28; 95% CI, 0.95–1.72), 96.6% versus 97.8% (HR = 1.09; 95% CI, 0.61–1.94), and 15.5% versus 15.1% (HR = 0.99; 95% CI, 0.72–1.37), in the treatment groups.ConclusionsDespite a decrease in the number of new BCs, there was no tumor stage shift, and OS did not vary.

show abstract

What Has Changed During the COVID-19 Pandemic? - The Effect on an Academic Breast Department in Portugal

Cited by 5 publications

References 19 publications

Changes in breast cancer staging trends among Egyptian women after COVID-19: A retrospective single-center study

Changes in breast cancer staging trends among Egyptian women after COVID-19: A retrospective single-center study

COVID-19 e rastreamento do câncer de mama no Brasil: uma análise comparativa dos períodos pré-pandêmico e pandêmico

Impact of the COVID‐19 pandemic on clinical presentation, treatments, and outcomes of new breast cancer patients: A retrospective multicenter cohort study

Contact Info

Product

Resources

About